// App-Quantinova.ai

587 : Superior anti-tumor effects of an anti-HLA-DR IgG4 antibody, IMMU-114, in chronic and acute lymphocytic leukemia (CLL and ALL): Comparison to anti-CD20 therapy, chemotherapy, or combined with kinase inhibitors

Researchers

Presenter

  • Thomas M. Cardillo

Principal Investigators

  • Maria Zalath

  • Roberto Arrojo

  • Robert M. Sharkey

  • David M. Goldenberg

Medical Centers

  • Immunomedics Inc., Morris Plains, NJ

Locations

  • United States

Companies

  • Immunomedics, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Non-Hodgkin's Lymphoma

  • Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • Breakpoint Cluster Region

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

Drug/Treatment

  • Doxorubicin

  • IMMU-114

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01728207

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved